Philips Gains FDA Clearance for Verida AI-Spectral CT Enabling 270 Exams Daily
Royal Philips secured U.S. FDA 510(k) clearance for its AI-powered Spectral CT Verida system, enabling always-on spectral imaging with a third-generation Nano-panel Precise dual-layer detector and deep-learning reconstruction. Verida reconstructs 145 images per second—twice as fast as its predecessor—supporting up to 270 exams daily across radiology, cardiology and oncology.
1. FDA Clearance Received
Philips received U.S. FDA 510(k) clearance for its Spectral CT Verida system on April 16, 2026, marking its first AI-powered detector-based spectral CT approval in the United States.
2. AI Reconstruction and Detector Tech
Verida integrates a third-generation Nano-panel Precise dual-layer detector with Spectral Precise Image AI reconstruction, reducing noise and enhancing image quality while allowing customizable de-noising settings for clinicians.
3. Clinical Workflow and Performance
The system reconstructs 145 images per second—twice as fast as its predecessor—and supports up to 270 exams daily without workflow changes, delivering conventional and spectral results simultaneously in under 30 seconds.
4. Market Implications and Sales Potential
Clearance unlocks US market access for radiology, cardiology and oncology applications, positioning Philips to expand clinical adoption and drive higher CT system sales across major healthcare providers.